Neurocrine Biosciences | NBIX - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 3.61B 2.92B 2026-06
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
ALKERMES USD 501K 66.98M 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amgen USD 2.38B 556M 2026-06
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Cytokinetics USD -198.76M 7.27M 2026-06
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Exelixis USD 212.05M 1.58M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
Halozyme Therapeutics USD 229.91M 79.86M 2026-06
Incyte USD 585.6M 282.27M 2026-06
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Pfizer USD -248M 2.94B 2026-06
Prothena USD 32.72M 54.31M 2026-03
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Repligen USD 5.01M 3.32M 2026-06
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Teva Pharmaceutical Industries USD -576M 945M 2026-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.1B 68.4M 2026-06